News
-
According to MannKind Corporation, Hakan Edstrom has taken over as CEO after company founder Alfred Mann stepped down from that position effective January 9, 2015. Mann will become the Executive Chairman and “intends to remain… Read more . . .
-
According to Verona Pharma a Phase 1/2 trial of its RPL554 inhaled PDE3/4 inhibitor for the treatment of COPD has gotten underway with dosing of the first subjects. Plans are for recruitment of up to… Read more . . .
-
Hovione has announced the promotion of Filipe Gaspar to VP of R&D, reporting to CEO Guy Villax. Gaspar joined Hovione in 2003 and has held a number of positions at the company, including Director of… Read more . . .
-
Researchers at Wake Forest Baptist Medical Center have announced results of a study in which 60 patients with amnesic mild cognitive impairment or mild to moderate Alzheimer’s dementia received one of two doses of an… Read more . . .
-
Egalet Corporation, which is developing several treatments for chronic pain, has announced the acquisition of Sprix ketorolac tromethamine nasal spray from Daiichi Sankyo subsidiary Luitpold Pharmaceuticals for $7 million. Ketorolac is a non-steroidal anti-inflammatory drug… Read more . . .
-
Pharmaceutical propellant market leader Mexichem has announced its acquisition of a distribution and sale license for DuPont’s pharmaceutical grade Dymel 227ea/P propellant and says that it will market the product under its Zephex brand. Zephex… Read more . . .
-
Novartis has announced that it submitted New Drug Applications to the FDA for both the QVA149 indacaterol/glycopyrronium bromide and NVA237 glycopyrronium bromide DPIs in the fourth quarter of 2014. Both inhalers are meant for the… Read more . . .
-
Vectura has announced that it will partner with Janssen Biotech to develop inhaled dry powder anti-inflammatory products for the treatment of asthma and COPD. Janssen’s drug candidates will be developed using Vectura’s DPI delivery technology,… Read more . . .
-
Indian conglomerate SRF Limited has acquired DuPont’s Dymel pharmaceutical propellants for $20 million in cash, according to reports in the Indian press. SRF, which already has two technical grade HFA-134a plants, plans to build its… Read more . . .
-
Italian startup Plumestars has announced via Twitter that it has received orphan drug status from the EMA for its amikacin dry powder inhaler for the treatment of P. aeruginosa infections in cystic fibrosis patients. Here… Read more . . .
Upcoming Events
Sponsored by Intertek
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
October 19-October 20: MVIC Autumn Training 2026, Lund, Sweden
October 21-October 22: MVIC Symposium, Lund, Sweden
November 10-November 11: Rescon Europe 2026, Porto, Portugal
December 9-December 11: DDL 2026, Edinburgh, Scotland